Non-Viral Gene-Edited Manufacturing to Advance TCR-T Therapies
- Non-viral gene-edited TCR gene integration for potent TCR-T cell therapies
- Scalable manufacturing inputs to support scale-out and reduce timelines to FIH products
- Enable scalable, cost-effective TCR-T therapy delivery to meet growing clinical demand